tbuckley/cabot-search huggingface dataset:
PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States.
Authors: Johannes Uhlig, Stacey Stein, Kevin Kim
Journal: Journal of Clinical Oncology (2020)

e16647 Background: Novel oncological treatment strategies for hepatocellular carcinoma (HCC) include immunotherapies targeting programmed death protein 1 (PD-1). To date there is scarce data on the current real-world clinical utilization of immunotherapy for HCC in the US. Methods: The Flatiron Health EHR-derived de-identified database was queried in October 2019 for adult patients with advanced HCC. PD-1 targeted immunotherapy (PD-1 IMT) included Nivolumab and Pembrolizumab. Overall survival (OS) was evaluated using Cox proportional hazards models. Multivariable analyses adjusted for patient demographics (age, gender, race), documented liver disease risk factors (obesity, diabetes, alcohol abuse, hepatitis), documented liver disease complication (ascites, encephalopathy), local HCC treatment (resection, radiofrequency ablation, transarterial chemoembolization [TACE], transarterial radioembolization [TARE]) and systemic Sorafenib. Subgroup analyses were performed in patients with documented clinical performance status (Eastern Cooperative Oncology Group; ECOG) and albumin/bilirubin results (all measured nearest to HCC diagnosis). Results: A total of 2,912 patients with advanced HCC were included, of which n = 345 (11.8%) received PD-1 IMT. Utilization of PD-1 IMT continuously increased from 2004, accounting for 20.9% of all cases in 2018/19. Patients treated with and without PD-1 IMT were comparable regarding demographics, comorbidities and liver disease. PD-1 IMT was more commonly administered at academic centers (20.3% vs. 13% in non-academic centers, p &lt; 0.001), and in patients receiving Sorafenib, TACE, TARE or HCC resection (vs. none of these treatments, each p &lt; 0.05). Median follow-up time was 36.1 months. In univariate analyses, administration of PD-1 IMT was associated with longer OS (vs. no PD-1 IMT; HR = 0.67, 95% CI: 0.58-0.78, p &lt; 0.001; OS rates in the table). In multivariable analyses, PD-1 IMT receipt was an independent prognosticator (vs. no PD-1 IMT; HR = 0.54, 95% CI: 0.46-0.63, p &lt; 0.001). In a subset of n = 1560 patients, this effect persisted after adjustment for ECOG, albumin and bilirubin results (HR = 0.58; 95% CI: 0.48-0.69, p &lt; 0.001). Conclusions: PD-1 targeted immunotherapy is increasingly used for advanced HCC, accounting for up to 20.9% of cases in 2018/19. After adjustment for potential confounders, immunotherapy was associated with an overall survival benefit. [Table: see text]
Low-density lipoproteinimmune complexes in patients with type 2 diabetes
Authors: Xue-qin Wang, CUIShi-wei, Yan JiN, Guo-hua Tao, Jin-feng Chen, Gang Wu
Journal: BMJ (2009)

：This study was designedto observe the clinical value of low-density lipoprotein immune complexes (LDL-ICs) inpatients with type 2 diabetes mellitus (T2DM). Fifty-four patients with type 2 diabetes +macroangiopathy (DM-MA group), 48 patients with type 2 diabetes (DM group), 45 patientswith macroangiopathy ( MA group), and 30 normal controls ( NC group) were enrolled.LDL-ICs levels in the DM-MA group were significantly higher than those in the other threegroups. The levels of LDL-ICs in the MA group were higher than those in the NC and DMgroups. There was a significant difference in LDL-ICs between the DM and NC groups.LDL-ICs levels were positively related with body mass index (BMI), glycesylated hemoglobinAlc(HbAlc), blood pressure, total cholesterol, and triglyceride. There was no significantrelationship between low-density lipsprotcin cholesterol and LDL-ICs. A significantlynegative correlation was recorded between high-density lipoprotein cholesterol andLDL-ICs. Our study suggests that LDL-ICs, blood pressure, and HbAlc may be risk factors ofmacroangiopathy in type 2 diabetic patients.
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
Authors: HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese, Ji Hoon Jeong
Journal: Drugs (2020)
Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy: A U.S. Food and Drug Administration pooled analysis.
Authors: Mitchell Steven Anscher, Shaily Arora, Chana Weinstock, Rachael Lubitz, Anup Amatya, Mallorie Fiero, Shenghui Tang, Pradeep Bandaru, Jacquelyn Sanchez, Andrew Girvin, Chad Tang, Laleh Amiri-Kordestani, Marc Robert Theoret, Richard Pazdur, Julia A. Beaver
Journal: Journal of Clinical Oncology (2020)

3018 Background: Immune checkpoint inhibitors (ICIs) are widely used in the treatment of multiple advanced malignancies. Radiotherapy (RT) has been used in combination with ICIs to activate tumor-specific T cell responses, and RT also promotes non-specific acute and chronic inflammatory responses both locally and systemically. More than 50% of patients receive RT at some point during their course of cancer therapy, and relatively little information is available pertaining to the impact of RT, if any, on the risk of adverse events (AEs) in patients receiving ICIs. Methods: Pooled data from prospective trials of ICIs submitted to the FDA in initial or supplemental BLAs or NDAs through 12/2019 were included (N=66). Trials from applications that were withdrawn or not approved were not included. Patients were subdivided by whether or not radiotherapy was administered at any time during the course of their cancer treatment. AEs common to both ICI treatment and RT were identified to focus on the following reactions: neutropenia, thrombocytopenia, colitis, hepatitis, pneumonitis, and myocarditis. Descriptive statistics were used to examine AEs associated with the use of radiation and ICIs. Results: A total of 25,836 patients were identified, of which 9087 (35%) received RT and 16,749 (65%) did not. Radiation was associated with similar rates of AEs overall with numerically higher hematologic toxicities and pneumonitis and numerically lower colitis, hepatitis and myocarditis (Table). Patients receiving RT were more likely to experience Grade 3-5 hematologic toxicities compared to those not receiving RT. Conclusions: To our knowledge, this is the largest report of AE risk associated with the use of radiation and ICIs. Our results show that the incidence of hematologic toxicity and pneumonitis in patients receiving RT may be slightly higher. Analysis to determine comparability of baseline demographic characteristics, comprehensive AE profile, and timing of RT is underway. [Table: see text]
Efficacy of telotristat ethyl: A peripheral tryptophan hydroxylase inhibitor that blocks serotonin biosynthesis against cultured liposarcoma, colon cancer, and cholangiocarcinoma cell lines.
Authors: Harvey J. Kliman, Ivy S Ling, Kristin M Milano
Journal: Journal of Clinical Oncology (2020)

e15602 Background: Serotonin (5-HT) is most often considered a neurotransmitter—but in reality its main function is to promote cell proliferation at the site of wound healing via platelet degranulation. We tested the hypothesis that blocking 5-HT production in cancer cells might lead to their death by exposure to a specific tryptophan hydroxylase (TPH) inhibitor: telotristat ethyl (TE). The advantage of this TPH inhibitor is that it does not cross the blood brain barrier and therefore can be used to treat peripheral cancers without danger of interfering with central nervous system 5-HT production. Methods: Three cancer cell lines were tested: liposarcoma (94T778), colon cancer (HT-29), and cholangiocarcinoma (TFK-1). The cells were grown with 0, 5, 15 and 30 µM TE, plated into four-chambered slides with an initial confluence of at least 30%, and cultured for 24-96 H. At the end of each 24 hour period slides were removed, washed, fixed, and stained with hematoxylin for density assessment. Experiments were performed in triplicate and repeated in at least three separate experiments. Cell confluence was determined under low power microscopic examination. Results: In the absence of TE the three cell lines increased their confluence from approximately 30% to 83±5.8% (94T778), 68±11% (HT-29), and 60±16% (TFK-1) over 96 H. When the 94T778 cells were exposed to increasing concentrations of TE their confluence decreased progressively. At a dose of 30 µM cell confluence at 24 H was 3±0%, at 48 H 0.3±0.6%, at 72 H 0±0%, and at 96 H 0±0%. For the HT-29 cells, cell confluence in the 30 µM TE groups were 12±8%, 3±3%, 7±5% and 2±1% at 24, 48, 72 and 96 H, respectively. For the TFK-1cells, cell confluence in the 30 µM TE groups were 7±3%, 20±14%, 17±14% and 24±16% at 24, 48, 72 and 96 H, respectively. Conclusions: Telotristat ethyl is a potent inhibitor of tumor cell line growth. However, the efficacy of this inhibition varies between cell lines. The liposarcoma cell line was most sensitive to TE, with the cholangiocarcinoma cell line being moderately impacted. The colon cancer cell line was intermediate between these two. The differences in response to TE may be related to the specific expression of TPH in any particular cell line, with cancers that are more dependent on 5-HT production being most impacted by TPH blockade. Just as ER PR positive breast cancers are sensitive to blockade of these receptors, TPH positive cancers may be successfully targeted by specific inhibition of the 5-HT biosynthetic pathway.
Improving the ability of standardized diagnosis and treatment of diabetes mellitus based on practice at grass-roots level
Authors: Lan Zhu, Ling Shi, Shanzhu Zhu, Weiping Jia
Journal: BMJ (2019)

《2型糖尿病基层诊疗指南（实践版·2019）》在《国家基层糖尿病防治管理指南（2018）》的基础上，又着重对2型糖尿病的特点、识别、转诊、筛查、预防和管理流程进行较详细介绍，并对基层诊疗中较薄弱的胰岛素治疗和容易忽视的环节做出重要提示，以期为基层医生提供科学、同质化、实用、可操作性强的2型糖尿病诊疗决策指导。
Children in care can be vaccinated against parents’ wishes without court action
Authors: Clare Dyer
Journal: BMJ (2020)

Local authorities will be allowed to get children in care vaccinated despite opposition from their parents without asking for court approval, three senior judges have ruled.1

Councils have a shared parental responsibility under the Children Act 1989 for children in their care and the power to take decisions about them, provided they are acting to safeguard or promote the child’s welfare. But decisions on whether to vaccinate have traditionally been treated as so serious that, if the child’s parents opposed it, a High Court judge was asked to decide.

In February Mr Justice Hayden ruled that the Children Act gave the London Borough of Tower …
预激综合征的心电图特征
Authors: 刘文玲, 王玉梅
Journal: BMJ (2009)

预激综合征(pre-excitation syndrome)是一种常见房室传导异常的疾病,最常见的类型为Wolf-Parkinson-White综合征(WPW),发病率为0.1%～3.0%.其病理改变为心房与心室之间存在异常传导通路(旁路AP),从而引起部分心室肌提前激动,改变了心室肌激动的程序性、同步性及统一性.约40%～80%患者伴有其他心律失常.下面举例说明预激综合征的心电图表现。
社区医院治疗慢性支气管炎伴肺部感染一例
Authors: 沈乃芳
Journal: BMJ (2007)

患者男,80岁,因反复咳嗽咳痰15年,加重并伴呼吸困难3个多月于2006年4月6日入院.患者于15年前受凉后经常咳嗽咳痰,全年发作时间超过3个月,冬季频繁,症状逐年加重,活动后出现气喘.3个多月前因咳嗽咳痰加重,呼吸困难伴意识模糊3 d于2005年12月28日急诊入住专科医院ICU病房,入院时痰堵现象严重,血氧饱和度75%,给予气管切开造口置管、呼吸机辅助呼吸通气、抗感染、止咳化痰、活血化淤和营养支持等治疗。
Vitamin C, Hydrocortisone, and Thiamine for Septic Shock—In Reply
Authors: Tomoko Fujii, Andrew A. Udy, Rinaldo Bellomo
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Energy metabolism in patients with chronic viral hepatitis and posthepatitic cirrhosis
Authors: 于淑清, 孟庆华, 李玉贤, 冯岩梅, 倪明美, 王金环, 王欣
Journal: BMJ (2007)

目的 了解慢性肝炎(慢肝)与肝炎后肝硬化(肝硬化)患者的物质能量代谢与摄入特点,以有效指导营养治疗.方法 采用间接测热法对60例慢肝(慢肝组)和60例肝硬化患者(肝硬化组)的静息能量消耗水平进行测定,分别与Harris-Benedict公式计算的基础能量消耗和膳食调查计算的食物能量摄入进行比较;分析静息能量消耗与营养评价指标的相关性.结果 肝硬化组的静息能量消耗(77±21)kJ·kg-1·d-1,低于基础能量消耗(95±16)kJ·kg-1·d-1(t=-6.49,P＜0.01),能量摄入(102±33)kJ·kg-1·d-1,是静息能量消耗的1.42±0.61倍,其中蛋白质摄入(0.84±0.31)g·kg-1·d-1,是静息蛋白质消耗[(1.11±0.42)g·kg-1·d-1]的0.85±0.52倍,呈负氮平衡(-6.29±4.62);慢肝组的静息能量消耗[(93±18)kJ·kg-1·d-1]与基础能量消耗[(98±8)kJ·kg-1·d-1]比较,差异无统计学意义(P＞0.05),能量摄入为(127±34)kJ·kg-1·d-1,是静息能量消耗的1.41±0.43倍,其中蛋白质摄入(1.02±0.29)g·kg-1·d-1,是静息蛋白质消耗(0.87±0.34)g·kg-1·d-1的1.31±0.61倍,呈负氮平衡(-2.02±4.07);与慢肝组比较,肝硬化组的静息能量消耗、能量及三大能量营养素摄入量、血清白蛋白和前白蛋白水平均显著低下(P＜0.01),体重下降明显(P＜0.01),负氮平衡严重(P＜0.01);肝硬化组的能量摄入与静息能量消耗和基础能量消耗的比值呈正相关(P＜0.05),血清前白蛋白与蛋白质氧化率呈负相关(P＜0.05).结论 肝硬化患者的静息能量消耗呈低代谢状态;负氮平衡是慢肝与肝硬化患者的共同营养问题;早期预防慢性肝病患者的营养不良能够改善其远期预后。
Survey on nicotine dependence among male outpatients in Weifang community health center
Authors: Yao Liu, Shijie Fu, Zhaohui Du, Dongmei Luo, Enting Zhou, Minghui Peng, Shanzhu Zhu
Journal: BMJ (2015)

Objective
To estimate nicotine dependence level and its influencing factors among male outpatients in community health centers.


Methods
A cross-sectional study on smoking behaviors was conducted among 805 male outpatients in Weifang community health center, Shanghai. Fagerstrom test for nicotine dependence (FTND) and multiple linear regression model were used to analyze the risk factors of nicotine dependence.


Results
The current smoking prevalence of male outpatients was 44.8%(361/805)and the average FTND score for current smokers was 3.6 (SD: 2.7). The low, moderate and high nicotine dependence rates were 52.1%, 21.0% and 26.9%, respectively. Multiple linear regression model showed that risk factors of nicotine dependence were divorce or bereavement of spouse(β=2.87, t=3.74, P=0.000), junior high school level education(β=0.93, t=2.26, P=0.025), duration of smoking>30 years(β=1.79, t=2.18, P=0.030); while age≥66 years(β=-1.73, t=1.99, P=0.048), strong desire of quitting(β=-0.70, t=2.14, P=0.033)were protective factors of nicotine dependence.


Conclusions
The rate of moderate and high nicotine dependence among male outpatients in community health center is high. Age, marital status, level of education, duration of smoking and desire of quitting are influencing factors of nicotine dependence.


Key words: 
Tobacco use disorder; Smoking; Community health centers
Clinical analysis and intervention strategies in 67 cases of pregnancy complicated with heart failure
Authors: Yong Wang, Ping Tang, Jing Jiang
Journal: BMJ (2012)

To explore the clinical characteristic and intervention strategies for pregnancy complicated with heart failure. The clinical data of 67 pregnant women with heart failure during January 1998 to December 2010 were collected and analyzed.The rate of heart failure in pregnancy with heart diseases was 31％ (67/216).The causes of pregnancy complicated with heart failure were peripartum cardiomyopathy ( n =33,49％ ) and hypertensive disorder complicating with pregnancy heart disease( n =28,42％ ).Heart failure in pregnancy appeared at an average of (36.0 ± 2.7 ) weeks.The average terminating time of pregnant women with heart failure was ( 36.5 ± 2.1 ) weeks.Cesarean section was the main safe choice of delivery for pregnant women with heart failure.The average weight of newborns for pregnant women with heart failure was(2517 ±541 )g.The rate of neonatal asphyxia was 22％ (11/50).Strengthening routine antenatal examination and treating pregnant complications timely can prevent and reduce the incidence of heart failure.

Key words: 
Pregnancy complications, cardiovascular;  Pregnancy outcome
Immunogenicity and transcriptomic biology in Nottingham histologic grade 3 breast cancer.
Authors: Hideo Takahashi, Masanori Oshi, Mariko Asaoka, Li Yan, Kazuaki Takabe
Journal: Journal of Clinical Oncology (2020)

e12563 Background: Cancer biology dictates disease progression and prognosis of a tumor. Histological grade has been used as a proxy of tumor biology in various cancer types, although it depends on morphological analysis of the tissue. As such, Nottingham histological grade is recently incorporated into the 8 th edition of the AJCC Breast Cancer Staging. Herein, we hypothesized that Nottingham histological Grade3 breast cancer (BC) demonstrate strong immunogenicity in response to aggressive phenotypes, reflecting worse clinical outcomes. Methods: Clinicopathological data and transcriptomes were obtained from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), The Cancer Genome Atlas (TCGA) Invasive breast carcinoma (BRCA) cohort, and GSE25066. While METABRIC was used as a training cohort, the other two cohorts served as validation cohorts. As TCGA did not contain pathological information, Nottingham histological grade was manually collected through the Text Information Extraction Systems (TIES). Results: 2876 patients were analyzed in this study. Grade1 tumors were 274 patients (9.5%), Grade2 tumors 1185 patients (41.2%), and Grade3 tumors 1417 patients (49.3%). Grade3 tumors were common in patients with Estrogen receptor (ER) negative (p &lt; 0.001), with Her2 and Basal molecular subtypes by the PAM50 classifier (p &lt; 0.001), and associated with increased MKI-67 expression (p &lt; 0.001). Disease-free survival (DFS) was significantly worse in Grade3 tumors in all cohorts. Gene set enrichment analysis (GSEA) demonstrated that Grade3 tumors significantly enriched immune activity related gene sets as well as cell proliferation and cell cycle related gene sets. CIBERSORT also demonstrated that Grade3 BCs were infiltrated with anti-cancer macrophage M1, follicular helper T cells, and activated NK cells (all p &lt; 0.001). Furthermore, Grade3 tumors were associated with more diverse T cell receptor (p = 0.001) and increased cytolytic activity (p &lt; 0.001). Lastly, T cell exhaustion markers, including PD-L1, PD-1, and CTLA4, were significantly elevated in Grade3 BCs (all p &lt; 0.001) as a negative feedback loop. Conclusions: Grade3 BCs demonstrated enhanced immunogenicity as well as aggressive transcriptomic features.
高血压的诊治
Authors: 吴东, 刘永太, 陈嘉林
Journal: BMJ (2011)

一、血压明显升高且有症状者需警惕高血压急症 高血压是社区的常见病,多数为原发性高血压,患者除偶尔头晕、头痛外常无症状,可在社区口服药物治疗.而高血压急症(hypertension emergency)是指短时间内血压急剧升高,并造成靶器官功能障碍的一种危重症,需住院并在心电监护的条件下应用静脉降压药物治疗。
Clinical characteristics and treatment of IgG4-related diseases: a report of 48 cases
Authors: Yong Zhang
Journal: BMJ (2019)

Forty eight patients with IgG-related disease (IgG-RD) were treated in Beijing Luhe Hospital, Capital Medical University between January 2014 and January 2017. The clinical features, organ involvement, laboratory findings and treatment of patients were analyzed. The median age of patients was 59 (29-78) years old. The most common symptoms were submandibular gland enlargement (20.8%), abdominal pain (18.8%), eyelid mass or edema (18.8%) and jaundice (16.7%). The involved organs mainly were submandibular glands (62.5%), lymph nodes (54.2%), lacrimal glands (45.8%), parotid glands (41.7%) and pancreas (31.3%). PET/CT was performed in 9 cases (18.8%), the SUVmax value was not correlated with the number of affected organs (r=0.511, P=0.160) and IgG4 (r=0.385, P=0.306). Histopathology showed increased lymphocytes and plasma cells in 46 cases (95.8%), eosinophilia in 15 cases (31.3%), and fibrous hyperplasia in 26 cases (54.2%). Twenty-three patients (47.9%) were treated with single glucocorticoid, 20 patients (41.6%) were treated with glucocorticoid combined immunosuppressants, 3 patients (6.3%) received surgical treatment, and 2 (4.2%) were observed with watch and wait regimen. Forty (97.9%) patients responded well to the initial treatment. Ten out of 23 cases (43.5%) in corticosteroid monotherapy group relapsed, while 6 out of 20 cases (30.0%) in corticosteroids plus immunosuppressive group relapsed, for whom the full dose of corticosteroid and immunosuppressive agents were still effective. IgG4-RD is a chronic inflammatory and fibrous sclerotic disease with multiple organ involvement, increase serum IgG4 level and tissue infiltration with large number of IgG4+cells. Hormone and immunosuppressive therapy is effective, and the overall prognosis is good.


Key words: 
Immunoglobulin G; IgG4-related disease; Clinical characteristics; Treatment outcome
社区家庭保健员培训效果分析
Authors: 张晓玲, 郑美玲, 任志英
Journal: BMJ (2011)

2007年北京市社区卫生服务管理中心(社管中心)推出社区慢性病防治的家庭保健员计划模式,并于2009年北京市卫生局开始在全市推广.本中心于2009年7月对330例门诊慢性病患者进行家庭保健员培训,现报道如下。
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a <i>STK11</i> mutation.
Authors: Josiah An, Melissa Yan, Nanmeng Yu, Adithya Chennamadhavuni, Muhammad Furqan, Timothy Kruser, Timothy L Sita, Ryan Nguyen, Lawrence Eric Feldman, Mary Pasquinelli, Nasser H. Hanna, Taher Abu Hejleh
Journal: Journal of Clinical Oncology (2020)

9033 Background: STK11 mutation ( STK11 m ) in patients with stage IV NSCLC is associated with inferior survival and poor response to immune check point inhibitors (ICI). The significance of STK11 m in patients (pts) with stage III NSCLC treated with concurrent chemoradiation (CCRT) with and without consolidation ICI is unknown. Methods: Patient demographics, disease characteristics, treatment received and outcomes in pts with stage III NSCLC that harbor STK11 m were retrospectively reviewed from 4 cancer centers. A cohort of pts with stage III NSCLC and wild type STK11 (STK11 w ) from the University of Iowa served as a comparison group. SPSS version 25 was used for data analysis. Results: 75 pts with stage III NSCLC who had gene sequencing were included. 16/75 (21%) had STK11 m . The clinical characteristics for the 16 STK11 m and 59 STK11 w pts showed ( STK11 m vs. STK11 w ): mean age: 58 vs. 64 yrs, non-squamous histology: 11/16 (69%) vs. 37/59 (63%), KRAS co-mutation: 6/16 (38%) vs. 11/59 (19%), TP53 co-mutation: 9/16 (56%) vs. 15/59 (25%), PD-L1 ≥ 50%: 2/16 (13%) vs. 10/59 (17%), received CCRT 11/16 (69%) vs. 59/59 (100%) and consolidation ICI 6/16 (38%) vs. 17/59 (29%). Regarding the 6 STK11 m pts who received ICI (4 pembrolizumab, 2 durvalumab), the median number of ICI infusions was 8 (range, 3-17) vs. 7 (range, 1-25) in the 17 pts with STK11 w who received ICI (durvalumab). Progression free survival (PFS) for the STK11 m vs. STK11 w pts who received CCRT but not ICI was (4.2 vs. 34.3 months, respectively. P = 0.168), for the STK11 m vs. STK11 w pts who received CCRT and ICI was (11.3 vs. 17.5 months, respectively. P = 0.174), and for the STK11 m vs. STK11 w pts who received CCRT regardless of receiving ICI (11.3 vs. 32.9 months, respectively. P = 0.021). The median overall survival for STK11 m pts (16 pts) was 25.5 months (95% CI, 13.7 to 37.2) while not yet reached for the STK11 w group. Conclusions: In stage III NSCLC, STK11 m was associated with inferior clinical outcomes. Larger studies are needed to identify the prognostic implications of STK11 m in stage III NSCLC and whether ICI impacts survival for this subgroup.